Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that following the completion of a detailed selection process, the Board has approved the appointment of BDO LLP as its new external auditor, subject to shareholder confirmation for the year ending 31 December 2021.
BDO will hold office until the next Annual General Meeting (in June 2022) at which point their appointment will be subject to shareholder approval. KPMG LLP has resigned as the Group’s auditor and has confirmed to the Group that, in accordance with Section 519 of the Companies Act 2006, there are no circumstances in connection with its resignation which it considers need to be brought to the attention of the Company’s shareholders or creditors.
Paul Fry, Chair of the Audit Committee of Avacta Group, commented:
“The Board would like to thank KPMG for their work as auditor since 2010, supporting the Group through a period of considerable growth and transition into a clinical stage company. We look forward to working with BDO and building a similar long-term relationship.”